USSN: 10/809,176

Attorney Docket: 2003.002 US

Response to Office Action of September 21, 2007

## Amendments to the Claims:

## Claims 1-2 (Canceled).

- 3. (Currently amended): The classic IBDV mutant according to claim 1, A classic infectious bursal disease virus (IBDV) mutant that expresses a VP2 protein that binds with monoclonal antibody (moab) B69, wherein the VP2 protein also binds with moab 67, secreted by hybridoma cell lines HB-9437 and HB-11122, deposited at the ATCC, Rockville, USA, respectively, wherein the mutant comprises one or more mutations in a classic VP2 coding region, such that the coding region comprises,
- (i) a codon for the amino acid at position 222 encoding an amino acid selected from the group consisting of serine and threonine, and (ii) a nucleotide sequence encoding an amino acid sequence selected from the group consisting of SEQ ID. No. 1, SEQ ID. No. 2, SEQ ID. No. 3, SEQ ID. No. 4 and SEQ ID. No. 5 at positions 318-323.
- 4. (Currently amended): [[A]] <u>The</u> classic IBDV mutant according to claim 3, wherein the coding region comprises a codon for the amino acid at position 330 encoding an amino acid selected from the group consisting of arginine and serine.
- 5. (Currently amended): The classic IBDV mutant according to elaim-1, claim 3, wherein the mutant comprises one or more mutations in a VP2 coding region of IBDV strain D78.
- 6. (Currently amended): The classic IBDV mutant according to elaim 1, claim 3, wherein the mutant comprises a genomic segment A of a classic IBDV, preferably of IBDV strain D78.

USSN: 10/809,176

Attorney Docket: 2003.002 US

Response to Office Action of September 21, 2007

7. (Currently amended): An immunogenic composition for raising antibodies in poultry against IBDV comprising a classic IBDV mutant according to claim 1, claim 3, together with a pharmaceutical pharmaceutically acceptable carrier or diluent.

- 8. (Previously presented): The immunogenic composition according to claim 7, wherein the classic IBDV mutant is in a live form.
- 9. (Currently amended): The immunogenic composition according to claim 7, wherein the vaccine which further comprises one or more vaccine components immunogens of other pathogens infectious to poultry.
- 10. (Currently amended): The immunogenic composition according to claim 7, wherein the vaccine which comprises an adjuvant.

Claims 11-19 (Canceled).

- 20. (New): A classic infectious bursal disease virus (IBDV) mutant that expresses a VP2 protein that binds with monoclonal antibody (moab) B69, wherein the VP2 protein also binds with moab 67, secreted by hybridoma cell lines HB-9437 and HB-11122, deposited at the ATCC, Rockville, USA, respectively, wherein the mutant comprises one or more mutations in a classic VP2 coding region, such that the coding region comprises,
- (i) a codon for the amino acid at position 222 encoding an amino acid selected from the group consisting of serine and threonine, and
- (ii) a nucleotide sequence encoding an amino acid sequence selected from the group consisting of SEQ ID. No. 2, SEQ ID. No. 3, SEQ ID. No. 4 and SEQ ID. No. 5 at

USSN: 10/809,176

Attorney Docket: 2003.002 US

Response to Office Action of September 21, 2007

positions 318-323.

21. (New): A classic IBDV mutant according to claim 20, wherein the coding region comprises a codon for the amino acid at position 330 encoding an amino acid selected from the group consisting of arginine and serine.

- 22. (New): The classic IBDV mutant according to claim 20, wherein the mutant comprises one or more mutations in a VP2 coding region of IBDV strain D78.
- 23. (New): The classic IBDV mutant according to claim 20, wherein the mutant comprises a genomic segment A of IBDV strain D78.
- 24. (New): An immunogenic composition for raising antibodies in poultry against IBDV comprising a classic IBDV mutant according to claim 20, together with a pharmaceutically acceptable carrier or diluent.
- 25. (New): The immunogenic composition according to claim 24, wherein the classic IBDV mutant is in a live form.
- 26. (New): The immunogenic composition according to claim 24, which further comprises one or more of other pathogens infectious to poultry.
- 27. (New): The immunogenic composition according to claim 24, which comprises an adjuvant.